The Conversation (0)
Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT
CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational MRNA therapeutics have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 - June 2 in Chicago, IL.
The presentation details are as follows:
Oral Presentation:
Abstract #9500: Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 study
Session Type/Title: Oral Abstract Session - Melanoma/Skin Cancers
Data & Time: June 1, 8:00 AM - 11:00 AM CT
Presenter: Matteo S. Carlino, MBBS, PhD, FRACP
Poster Presentations:
Abstract #9564: Intismeran autogene to induce de novo neoantigen-specific T cells as adjuvant therapy in melanoma
Session Type/Title: Poster Session - Melanoma/Skin Cancers: Poster Board #280
Date & Time: May 31, 9:00 AM - 12:00 PM CDT
Presenter: Ryan J. Sullivan, MD
Abstract #TPS7580: A phase 1/2 study of mRNA-2808 in participants with relapsed or refractory multiple myeloma
Session Type/Title: Poster Session - Hematologic Malignancies - Plasma Cell Dyscrasia: Poster Board #457b
Date & Time: June 1, 9:00 AM - 12:00 PM CDT
Presenter: Hans C. Lee, MD
Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.
Moderna Investor Event
Moderna will host a live webcast on Monday, June 1, from 6:15 - 7:15 PM CDT. The webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.Modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Moderna Contacts
Media:
Chris Ridley
Vice President, Global Head of Communications
+1 617-800-3651
Chris.Ridley@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
